285 related articles for article (PubMed ID: 26688076)
1. A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation.
Hatzoglou V; Yang TJ; Omuro A; Gavrilovic I; Ulaner G; Rubel J; Schneider T; Woo KM; Zhang Z; Peck KK; Beal K; Young RJ
Neuro Oncol; 2016 Jun; 18(6):873-80. PubMed ID: 26688076
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effectiveness of MRI perfusion and fluorine-18 FDG PET-CT for differentiating radiation injury from viable brain tumor: a preliminary retrospective analysis with pathologic correlation in all patients.
Hatzoglou V; Ulaner GA; Zhang Z; Beal K; Holodny AI; Young RJ
Clin Imaging; 2013; 37(3):451-7. PubMed ID: 23068052
[TBL] [Abstract][Full Text] [Related]
3. Role of FDG-PET/MRI, FDG-PET/CT, and Dynamic Susceptibility Contrast Perfusion MRI in Differentiating Radiation Necrosis from Tumor Recurrence in Glioblastomas.
Hojjati M; Badve C; Garg V; Tatsuoka C; Rogers L; Sloan A; Faulhaber P; Ros PR; Wolansky LJ
J Neuroimaging; 2018 Jan; 28(1):118-125. PubMed ID: 28718993
[TBL] [Abstract][Full Text] [Related]
4. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
[TBL] [Abstract][Full Text] [Related]
5. Integrated PET-MRI for Glioma Surveillance: Perfusion-Metabolism Discordance Rate and Association With Molecular Profiling.
Seligman L; Kovanlikaya I; Pisapia DJ; Naeger DM; Magge R; Fine HA; Chiang GC
AJR Am J Roentgenol; 2019 Apr; 212(4):883-891. PubMed ID: 30779663
[TBL] [Abstract][Full Text] [Related]
6. Prospective comparative diagnostic accuracy evaluation of dynamic contrast-enhanced (DCE) vs. dynamic susceptibility contrast (DSC) MR perfusion in differentiating tumor recurrence from radiation necrosis in treated high-grade gliomas.
Zakhari N; Taccone MS; Torres CH; Chakraborty S; Sinclair J; Woulfe J; Jansen GH; Cron GO; Thornhill RE; McInnes MDF; Nguyen TB
J Magn Reson Imaging; 2019 Aug; 50(2):573-582. PubMed ID: 30614146
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH
Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
[TBL] [Abstract][Full Text] [Related]
8. Utility of Dynamic Susceptibility Contrast Perfusion-Weighted MR Imaging and
Qiao Z; Zhao X; Wang K; Zhang Y; Fan D; Yu T; Shen H; Chen Q; Ai L
AJNR Am J Neuroradiol; 2019 Feb; 40(2):253-259. PubMed ID: 30655259
[TBL] [Abstract][Full Text] [Related]
9. Accurate differentiation of recurrent gliomas from radiation injury by kinetic analysis of α-11C-methyl-L-tryptophan PET.
Alkonyi B; Barger GR; Mittal S; Muzik O; Chugani DC; Bahl G; Robinette NL; Kupsky WJ; Chakraborty PK; Juhász C
J Nucl Med; 2012 Jul; 53(7):1058-64. PubMed ID: 22653792
[TBL] [Abstract][Full Text] [Related]
10. Narrow interval dual phase 18F-FDG PET/CT: A practical approach for distinguishing tumor recurrence from radiation necrosis in brain metastasis.
Aggarwal A; Aggarwal AK; Prakash S; Vile DJ; Aggarwal A
Medicine (Baltimore); 2024 May; 103(18):e37789. PubMed ID: 38701250
[TBL] [Abstract][Full Text] [Related]
11. Glioma Recurrence Versus Radiation Necrosis: Single-Session Multiparametric Approach Using Simultaneous O-(2-18F-Fluoroethyl)-L-Tyrosine PET/MRI.
Jena A; Taneja S; Gambhir A; Mishra AK; Dʼsouza MM; Verma SM; Hazari PP; Negi P; Jhadav GK; Sogani SK
Clin Nucl Med; 2016 May; 41(5):e228-36. PubMed ID: 26859208
[TBL] [Abstract][Full Text] [Related]
12. Comparison of (11)C-methionine, (11)C-choline, and (18)F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis.
Takenaka S; Asano Y; Shinoda J; Nomura Y; Yonezawa S; Miwa K; Yano H; Iwama T
Neurol Med Chir (Tokyo); 2014; 54(4):280-9. PubMed ID: 24305028
[TBL] [Abstract][Full Text] [Related]
13. Comparison of effects of 18F-FDG PET-CT and MRI in identifying and grading gliomas.
Song PJ; Lu QY; Li MY; Li X; Shen F
J Biol Regul Homeost Agents; 2016; 30(3):833-838. PubMed ID: 27655507
[TBL] [Abstract][Full Text] [Related]
14. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI.
Kim YH; Oh SW; Lim YJ; Park CK; Lee SH; Kang KW; Jung HW; Chang KH
Clin Neurol Neurosurg; 2010 Nov; 112(9):758-65. PubMed ID: 20619531
[TBL] [Abstract][Full Text] [Related]
15. Differentiating between Central Nervous System Lymphoma and High-grade Glioma Using Dynamic Susceptibility Contrast and Dynamic Contrast-enhanced MR Imaging with Histogram Analysis.
Murayama K; Nishiyama Y; Hirose Y; Abe M; Ohyu S; Ninomiya A; Fukuba T; Katada K; Toyama H
Magn Reson Med Sci; 2018 Jan; 17(1):42-49. PubMed ID: 28515410
[TBL] [Abstract][Full Text] [Related]
16. Differentiation between intra-axial metastatic tumor progression and radiation injury following fractionated radiation therapy or stereotactic radiosurgery using MR spectroscopy, perfusion MR imaging or volume progression modeling.
Huang J; Wang AM; Shetty A; Maitz AH; Yan D; Doyle D; Richey K; Park S; Pieper DR; Chen PY; Grills IS
Magn Reson Imaging; 2011 Sep; 29(7):993-1001. PubMed ID: 21571478
[TBL] [Abstract][Full Text] [Related]
17. Preoperative characterization of indeterminate large adrenal masses with dual tracer PET-CT using fluorine-18 fluorodeoxyglucose and gallium-68-DOTANOC: initial results.
Naswa N; Sharma P; Soundararajan R; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Diagn Interv Radiol; 2013; 19(4):294-8. PubMed ID: 23439252
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic accuracy of dynamic gadoxetic-acid-enhanced MRI and PET/CT compared in patients with liver metastases from neuroendocrine neoplasms.
Armbruster M; Zech CJ; Sourbron S; Ceelen F; Auernhammer CJ; Rist C; Haug A; Singnurkar A; Reiser MF; Sommer WH
J Magn Reson Imaging; 2014 Aug; 40(2):457-66. PubMed ID: 24347148
[TBL] [Abstract][Full Text] [Related]
19. Is integrated 18F-FDG PET/MRI superior to 18F-FDG PET/CT in the differentiation of incidental tracer uptake in the head and neck area?
Schaarschmidt BM; Gomez B; Buchbender C; Grueneisen J; Nensa F; Sawicki LM; Ruhlmann V; Wetter A; Antoch G; Heusch P
Diagn Interv Radiol; 2017; 23(2):127-132. PubMed ID: 28089955
[TBL] [Abstract][Full Text] [Related]
20. A new diagnostic marker for differentiating multicentric gliomas from multiple intracranial diffuse large B-cell lymphomas on 18F-FDG PET images.
Wang K; Zhao X; Chen Q; Fan D; Qiao Z; Lin S; Jiang T; Dai J; Ai L
Medicine (Baltimore); 2017 Aug; 96(32):e7756. PubMed ID: 28796066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
